(Q36150565)

12 August 2017

1 reference

title

ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis (English)

1 reference

12 August 2017

Icilio Cavero

1

1 reference

12 August 2017

William Crumb

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

509-530

1 reference

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Drug block of I(kr): model systems and relevance to human arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Safety pharmacology and risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

The impact of drug-induced QT interval prolongation on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Origins, practices and future of safety pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Increased late sodium current in myocytes from a canine heart failure model and from failing human heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Drug induced QT prolongation: lessons from congenital and acquired long QT syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Exploring the hidden danger of noncardiac drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Drugs, QT interval prolongation and ICH E14: the need to get it right

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Mechanisms of arsenic-induced prolongation of cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Pentamidine-induced long QT syndrome and block of hERG trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

ECG abnormalities in tricyclic antidepressant ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Mutation in the KCNQ1 gene leading to the short QT-interval syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

Short QT syndrome: pharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.509

21 January 2018

Identifiers

DOI

10.1517/14740338.4.3.509

1 reference

12 August 2017

1 reference